Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

NCT06106828

CompletedPhase 3

Sponsor: Hoffmann-La Roche

Conditions: Thyroid Eye Disease

Interventions: Satralizumab, Placebo

Countries: United States, Canada, China, France, Israel, Poland, Portugal, South Korea

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

\- Clinical diagnosis of TED based on CAS

Exclusion Criteria:

* Decrease in CAS or proptosis of \>≥ 2 points or ≥ 2 mm, respectively, in the study eye between Screening and Study Baseline (Day 1)
* Requiring immediate surgical ophthalmological intervention or planning corrective surgery or irradiation during the course of the study, in the judgment of the investigator
* Identified pre-existing ophthalmic disease that, in the judgment of the investigator, would preclude study participation or complicate interpretation of study results, including corneal decompensation unresponsive to medical management and including ophthalmic diseases that will likely require prohibited therapy during the study
* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study
* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of satralizumab
Locations (41)
  • San Diego, California, United States
  • Danbury, Connecticut, United States
  • Chicago, Illinois, United States
  • Philadelphia, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • San Antonio, Texas, United States
  • Edmonton, Alberta, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Beijing, China
  • Beijing, China
  • Beijing, China
  • Beijing, China
  • Xi'an, China
  • Nantes, France
  • Paris, France
  • Paris, France
  • Jerusalem, Israel
  • Petah Tikva, Israel
  • Ramat Gan, Israel
  • Bydgoszcz, Poland
  • Gdansk, Poland
  • Coimbra, Portugal
  • Seongnam-si, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • L'Hospitalet de Llobregat, Barcelona, Spain
  • Barcelona, Spain
  • Granada, Spain
  • + 11 more on CT.gov